Inflammatory Responses During Cardiopulmonary Bypass: Mechanisms, Mediators, and Management Strategies

Abstract: Cardiopulmonary bypass (CPB) induces a multifactorial systemic inflammatory response that significantly contributes to postoperative complications such as acute lung injury, renal dysfunction, and increased morbidity. This response is initiated by the contact of blood with non-physiologic surfaces and is exacerbated by ischemia-reperfusion injury and endotoxemia. Key inflammatory mediators involved include cytokines, complement proteins, bradykinin, prostaglandins, and activated leukocytes. Recent literature emphasizes novel strategies such as cytokine adsorption, coated circuits, and pharmacologic modulation to attenuate this cascade. This review consolidates both classic and recent evidence to provide a comprehensive understanding of CPB-induced inflammation and its management.

Introduction: Cardiopulmonary bypass remains essential in cardiac surgery but triggers a systemic inflammatory response syndrome (SIRS). The interaction of blood with artificial surfaces activates immune pathways, causing a cascade that includes leukocyte activation, complement generation, cytokine release, and endothelial dysfunction. The magnitude of this response is influenced by CPB duration, temperature, and circuit composition. With continuous advancements, understanding the biological basis of inflammation can optimize perfusion strategies and improve patient outcomes.

Mechanisms and Key Inflammatory Mediators in CPB:

1. Cytokines:Pro-inflammatory cytokines like IL-1β, IL-6, IL-8, and TNF-α are significantly elevated during CPB. IL-6 levels correlate with bypass duration and postoperative complications (Gravlee et al., 2008).These cytokines are secreted by monocytes, macrophages, and endothelial cells following contact activation and reperfusion injury.
2. Complement System Activation:The classical and alternative complement pathways are triggered by blood contact with extracorporeal surfaces. Activation results in the formation of C3a and C5a, leading to neutrophil chemotaxis, mast cell degranulation, and increased vascular permeability (Anderson et al., 1999).
3. Bradykinin:Generated via activation of the kallikrein-kinin system, bradykinin promotes vasodilation and capillary leakage. It contributes to hypotension and tissue edema during CPB (Despotis et al., 2001).
4. Prostaglandins:Especially PGE2, produced via COX-2 pathways, prostaglandins mediate fever, vasodilation, and inflammation. Their production is elevated in response to CPB-induced endothelial injury (Fransen et al., 2008).
5. Neutrophil Activation:Neutrophils are activated by cytokines and complement fragments. Activated neutrophils release proteolytic enzymes and reactive oxygen species (ROS), causing endothelial damage and capillary leakage (Rinder et al., 1995).
6. Endothelial Dysfunction:The combination of oxidative stress, inflammatory mediator release, and shear stress during CPB damages the endothelium, promoting edema and impaired microcirculation.

The Lung as an Immunologic Filter: The lungs play a key role in modulating systemic inflammation during CPB by filtering activated leukocytes and clearing cytokines such as IL-6 and TNF-α. Furthermore, the lungs metabolize bradykinin, limiting its systemic vasodilatory effects (Gravlee et al., 2008; Mukaida et al., 2020).

Strategies to Mitigate CPB-Induced Inflammation:

1. Use of Biocompatible Circuits:Heparin-coated and phosphorylcholine-coated circuits reduce contact activation and inflammatory mediator release. These surfaces modulate platelet and leukocyte activation (Saleem et al., 2023).
2. Pharmacologic Agents:Heparin has anti-inflammatory properties in addition to anticoagulation.Steroids such as methylprednisolone are used perioperatively to suppress cytokine production.Aprotinin and other serine protease inhibitors reduce fibrinolysis and inflammatory mediator release.
3. Temperature Management: Hypothermic CPB reduces metabolic demands and inflammatory responses, but recent studies advocate for normothermic CPB to improve end-organ perfusion and reduce cytokine surge (Tassawar et al., 2023).
4. Hemoadsorption and Cytokine Filtration:Devices like CytoSorb adsorb circulating cytokines such as IL-6 and TNF-α, potentially reducing postoperative organ dysfunction.
5. Miniaturized CPB Circuits (MECC):MECC reduces circuit surface area and priming volume, thereby limiting blood contact activation and inflammatory mediator generation (Ovrum et al., 2004).
6. Gradual Weaning from CPB: Controlled weaning allows the lungs to regain function gradually, preventing sudden increases in systemic cytokine levels (Gravlee et al., 2008).

Conclusion: The inflammatory response during cardiopulmonary bypass is a multifaceted process involving various cellular and humoral mediators. Understanding the interplay of cytokines, complement components, and endothelial dynamics has led to novel management strategies. Approaches such as coated circuits, pharmacologic agents, cytokine adsorption, and careful weaning from CPB are integral to minimizing inflammation-related morbidity. The evolving integration of new technologies and practices holds promise for improving patient outcomes.

References:

1. Gravlee GP, Davis RF, Stammers AH, Ungerleider RM. Cardiopulmonary Bypass: Principles and Practice. 3rd ed. Lippincott Williams & Wilkins; 2008.
2. Anderson RE, Brismar B, Barr G, Ivert T. Effects of cardiopulmonary bypass on cytokines and adhesion molecules. Eur J Cardiothorac Surg. 1999;16(4):500-506.
3. Despotis GJ, Avidan MS, Hogue CW. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72(5):S1821-1831.
4. Fransen E, Maessen JG, Dentener MA, et al. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest. 2008;133(2):387-393.
5. Rinder CS, Mathew JP, Rinder HM, et al. Neutrophil CD11b upregulation during CPB is associated with pulmonary dysfunction. J Thorac Cardiovasc Surg. 1995;110(6):1609-1617.
6. Mukaida N, Mahe Y, Matsushima K. Cooperative interaction of interleukin-8 and RANTES in activating and attracting neutrophils. J Leukoc Biol. 2020;108(2):627-636.
7. Ovrum E, et al. Improved results with off-pump versus on-pump coronary artery bypass surgery: a comparison of 1090 consecutive patients. Eur J Cardiothorac Surg. 2004;26(3):481-487.
8. Saleem M, Khan LN, Mushtaq A. Is there any significant impact of two different bio-compatible coated cardiopulmonary bypass circuits on circulating platelet drop. Biol Clin Sci Res J. 2023; 533.
9. Tassawar A, Fatima R, Mushtaq A. Blood Loss and Allogeneic Transfusion Requirements in Normothermic CPB Relative to Hypothermic CPB. J Cardiovasc Dis. 2023;20(1).